ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
Petrov D, Mansfield C, Moussy A, Hermine O. · 2017
Read ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? by Petrov D, Mansfield C, Moussy A, Hermine O. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5360725.txt.
Description
Dmitry Petrov, Colin Mansfield, Alain Moussy, and Olivier Hermine reviewed twenty years of failed ALS trials in Frontiers in Aging Neuroscience in 2017. ALS, a nerve disease that wastes muscle, kills tens of thousands of people a year across the world. Most patients live two to four years from first signs. One drug, riluzole, cleared in the mid nineteen nineties, gives a mild gain and stands alone.
More than sixty drug hopes have been tested since, and near all failed to show real gain in people. The team works through more than fifty trials to sort why. Two late hopes get close care. One is a pill, masitinib, tested in a wide, true-to-life patient set. The other is a drip drug, edaravone, whose one win came in a narrow slice of patients. The pair may soon join riluzole, but on unlike proof.
Catalog record
| CREATOR | Petrov D, Mansfield C, Moussy A, Hermine O. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |